London, 1 July 2013 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) today announces the signing of an exclusive commercialisation agreement with Theravance, Inc. (“Theravance”) (NASDAQ: THRX) for VIBATIV® (telavancin) in the Middle East and North Africa (“MENA”) region. VIBATIV® is a bactericidal, once-daily lipoglycopeptide injectable antibiotic for Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA).
Under the terms of the agreement, Hikma will have the exclusive rights to register, market and distribute VIBATIV® in 16 countries across MENA. The agreement will leverage Hikma’s strong local presence and regulatory expertise in MENA, with over 1,600 sales and marketing reps across the region.
MRSA is currently the most dangerous skin and soft tissue infection (“SSTI”) pathogen, causing serious infections in both hospitalised patients and patients in the community1. MRSA rates are increasing rapidly in many regions and there is a dynamic spread of strains across the globe.2
Said Darwazah, Hikma’s CEO said, “We are pleased to be partnering with Theravance to bring VIBATIV® to patients in the MENA region. VIBATIV® is an excellent product that will enhance our broad portfolio of anti-infective products and offers a good market opportunity. Strengthening our product portfolio through partnerships such as this continues to be a key component of our MENA growth strategy.”